BioPharmSignal logoBioPharmSignal

Biotech News

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

Spero Therapeutics (SPRO)Spero TherapeuticsConference / presentation

CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief...

Open original release

Related news

SPROSpero Therapeutics2023-09-06 08:05 EST

Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

SPROSpero Therapeutics2023-09-20 16:05 EST

Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference

ANTXAN2 Therapeutics2026-02-17 12:00 EST

AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference

ANTXAN2 Therapeutics2025-11-06 22:03 EST

AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference

ASMBAssembly Biosciences2026-05-28 20:05 EST

Assembly Biosciences Announces Upcoming Investor Conference Presentations

OGENOragenics2026-05-19 12:45 EST

Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21

ASMBAssembly Biosciences2025-10-14 11:00 EST

Assembly Biosciences Announces Upcoming Investor Conference Participation

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

ENTAEnanta Pharmaceuticals2026-05-04 11:00 EST

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

AVIRAtea2026-01-06 12:00 EST

Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

View all latest news

Spero Therapeutics

Spero Therapeutics is an anti-infective company focused on bacterial infections and novel antibiotics. Its story is centered on addressing drug-resistant pathogens and difficult infection settings.

Recent company news

SPROSpero Therapeutics2026-07-27 13:00 EST

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

SPROSpero Therapeutics2026-07-14 11:02 EST

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

SPROSpero Therapeutics2026-05-13 16:05 EST

Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update

SPROSpero Therapeutics2026-05-05 16:05 EST

Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026

SPROSpero Therapeutics2026-03-26 16:05 EST

Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update

Stock data

Close
1.18 USD
Market cap
163.86M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States